A Promising Strategy for Non-Arteritic Anterior Ischemic Optic Neuropathy: Intravitreal Mesenchymal Stem Cell Exosome

(E-pub Ahead of Print)

Author(s): Dongli Li, Yuanyuan Gong

Journal Name: Current Stem Cell Research & Therapy

Become EABM
Become Reviewer


Non-arteritic anterior ischemic optic neuropathy (NAION) is a leading cause of optic nerve-related permanent visual impairment among individuals of over 50 years of age after glaucoma. Because of perplexing disorder regarding its pathogenesis, there is still no widely accepted and established treatment plan. Mesenchymal stem cells (MSCs) are one of the rare stem cell types that therapeutic agents for immunomodulation and ischemic tissue repair in clinical practice. However, there are certain disadvantages in using MSCs, such as potential tumorigenicity, need for autologous collection, and short survival time. Previous evidence suggested that MSC-exosomes significantly attenuated post-ischemic neuronal damage and induced long-term neuroprotection associated with enhanced angiogenesis in MSCs.

Keywords: Exosome; Anterior ischemic optic neuropathy; Mesenchymal stem cellExosome; Anterior ischemic optic neuropathy; Mesenchymal stem cell

Rights & PermissionsPrintExport Cite as

Article Details

(E-pub Ahead of Print)
DOI: 10.2174/1574888X15666200814121849
Price: $95

Article Metrics

PDF: 48